Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo
暂无分享,去创建一个
Carolina Q. Sacramento | H. Castro-Faria-Neto | P. Bozza | C. Sacramento | T. Souza | J. Temerozo | R. Monteiro | O. Chaves | L. B. da Fonseca | N. Fintelman-Rodrigues | André C. Ferreira | M. Mattos | D. Pinto | Gabriel P. E. da Silveira | H. M. Pereira | A. Carlos | Joana da Costa Pinto d’Ávila | J. P. Viola | Leonardo Vazquez | J. R. Temerozo | G. E. D. da Silveira | T. M. Souza | Mayara Mattos | A. S. Carlos
[1] Michael McCoy. Pfizer to license COVID-19 antiviral , 2021, Chemical & Engineering News.
[2] Qi Zhang,et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332 , 2021, Protein & Cell.
[3] B. Souza,et al. SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021 , 2021, International Journal of Infectious Diseases.
[4] J. Tregoning,et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.
[5] S. Minaeian,et al. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients , 2021, Journal of medical virology.
[6] P. Venkatesan. Repurposing drugs for treatment of COVID-19 , 2021, The Lancet Respiratory Medicine.
[7] Carolina Q. Sacramento,et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 , 2021, The Journal of antimicrobial chemotherapy.
[8] M. Suchard,et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.
[9] Carolina Q. Sacramento,et al. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms , 2021, ACS omega.
[10] Nuno R. Faria,et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil , 2021, medRxiv.
[11] F. Bozza,et al. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes , 2021, Cell Death Discovery.
[12] Jakub M. Tomczak,et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 , 2021, Scientific Reports.
[13] Chunlong Ma,et al. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors , 2021, Proceedings of the National Academy of Sciences.
[14] D. Tegunov,et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir , 2021, Nature communications.
[15] M. Sturlese,et al. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332 , 2021, Journal of enzyme inhibition and medicinal chemistry.
[16] A. Dömling,et al. Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics , 2020, RSC medicinal chemistry.
[17] D. Barh,et al. Anisodamine Maintains the Stability of Intervertebral Disc Tissue by Inhibiting the Senescence of Nucleus Pulposus Cells and Degradation of Extracellular Matrix via Interleukin-6/Janus Kinases/Signal Transducer and Activator of Transcription 3 Pathway , 2020, Frontiers in Pharmacology.
[18] Carolina Q. Sacramento,et al. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms , 2020, bioRxiv.
[19] Jaeyong Lee,et al. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site , 2020, Nature Communications.
[20] V. Thiel,et al. Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.
[21] Carolina Q. Sacramento,et al. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production , 2020, Antimicrobial Agents and Chemotherapy.
[22] M. Müller,et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.
[23] Chunlong Ma,et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease , 2020, Cell Research.
[24] Janet S. Lee,et al. Practical Guidelines for Collection, Manipulation and Inactivation of SARS‐CoV‐2 and COVID‐19 Clinical Specimens , 2020, Current protocols in cytometry.
[25] A. Joachimiak,et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography , 2020, Nature Communications.
[26] Rei-Lin Kuo,et al. COVID-19: The first documented coronavirus pandemic in history , 2020, Biomedical Journal.
[27] S. Chaplin. COVID‐19: a brief history and treatments in development , 2020, Prescriber.
[28] A. Santucci,et al. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors , 2020, Scientific Reports.
[29] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[30] Bafna Khushboo. Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics , 2020 .
[31] G. Montelione,et al. Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics , 2020, ChemRxiv : the preprint server for chemistry.
[32] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[33] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[34] Dong Yang,et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] Kunqian Yu,et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs , 2020, Proceedings of the National Academy of Sciences.
[36] R. Hilgenfeld,et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.
[37] W. Liu,et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.
[38] Chunlong Ma,et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease , 2020, Cell Research.
[39] R. Wood. Atazanavir: its role in HIV treatment , 2008, Expert review of anti-infective therapy.
[40] K. Shadan,et al. Available online: , 2012 .